Receive 30% off all Monoclonal IHC antibodies with code "MONO-IHC-30"! Offer valid for US customers and available internationally through distributors.

Glucose 6 phosphatase 2 Polyclonal Antibody

Applications

  • WB
  • ELISA

Reactivity

  • Rat

Predicted Reactivity

  • Human
  • Mouse
  • Cow
  • Sheep
  • Horse
  • Rabbit
Overview
Catalog # bs-13386R
Product Name Glucose 6 phosphatase 2 Polyclonal Antibody
Applications WB, ELISA
Reactivity Rat
Predicted Reactivity Human, Mouse, Cow, Sheep, Horse, Rabbit
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from human Glucose 6 phosphatase 2/IGRP
Clonality Polyclonal
Clone # #REF!
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID 57818
Subcellular location Cell membrane
Synonyms G 6 Pase 2; G 6 Pase2; G6Pase 2; G6Pase2; G6PC 2; G6pc rs; G6pcrs; Glucose 6 phosphatase 2; Glucose 6 phosphatase, catalytic, 2; Glucose 6 phosphatase, catalytic, related; Glucose 6 phosphate catalytic 2; Islet specic G6CP related protein; Islet specic glucose 6 phosphatase; Islet specic glucose 6 phosphatase catalytic subunit related protein; G6PC2_HUMAN.
Background Glucose-6-phosphatase (G6Pase), is a multicomponent enzyme system that hydrolyzes glucose-6-phosphate in the final step of gluconeogenesis and gluconeolysis. G6Pase localizes to the endoplasmic reticulum, and while liver, kidney, and intestine are the only tissues that express the first identified isoform, G6Pase-alpha, a second form, designated G6Pase-, contributes to blood glucose homeostasis in a wider range of tissues. Islet-specific G-6-Pase catalytic subunit-related protein (IGRP), a homolog of the catalytic subunit of G6Pase, may play a role in the regulation of islet metabolism and in insulin secretion induced by metabolites. The exact catalytic acivity of IGRP is not defined. Identification of inhibitors of IGRP have potential therapeutic benefits for treatment of type 2 diabetes resulting from insulin secretion defects. Structurally, IGRP has been shown to be a glycoprotein held in the endoplasmic reticulum by nine transmembrane domains, which are then degraded in cells through the proteasome pathway generating MHC class I presented peptides.
Application Dilution
WB 1:300-5000
ELISA 1:500-1000